AstraZeneca Pharma India has received approval from the CDSO for the import, sale, and distribution of Durvalumab.

The stock is trading above its 5-day, 10-day, 20-day, 30-day, 50-day, 100-day, 150-day, and 200-day simple moving averages ...

This surge came after the company announced approval to import and distribute Durvalumab (Imfinzi) infusion in two dosages.

AstraZeneca topped the analyst consensus for net revenue and matched the analyst consensus for core EPS in Q2. See why I ...

This is to inform you that AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control ...

The uptick in AstraZeneca share price came after the company announced that it has received permission to import for sale and ...

AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive ...

Imfinzi is a human monoclonal antibody that targets the PD-L1 protein, whereas Imjudo focuses on the CTLA-4 protein.

The company has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution ...

The company has received approval to import, sell, and distribute Durvalumab Solution for infusion (Imfinzi) from the Central ...

Patients with limited-stage small cell lung cancer saw improvements in progression-free survival and overall survival with ...

The NIAGARA trial with Imfinzi is the first study to show an OS benefit in both the neoadjuvant and adjuvant settings.